553 related articles for article (PubMed ID: 30347480)
1. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.
Tanios GE; Doley PB; Munker R
Eur J Haematol; 2019 Feb; 102(2):157-162. PubMed ID: 30347480
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
3. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-associated autoimmune haemolytic anaemia.
Johnstone P; Khan O
BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31653618
[TBL] [Abstract][Full Text] [Related]
5. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.
Mamlouk O; Selamet U; Machado S; Abdelrahim M; Glass WF; Tchakarov A; Gaber L; Lahoti A; Workeneh B; Chen S; Lin J; Abdel-Wahab N; Tayar J; Lu H; Suarez-Almazor M; Tannir N; Yee C; Diab A; Abudayyeh A
J Immunother Cancer; 2019 Jan; 7(1):2. PubMed ID: 30612580
[TBL] [Abstract][Full Text] [Related]
8. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients.
Cortellini A; Buti S; Agostinelli V; Bersanelli M
Semin Oncol; 2019; 46(4-5):362-371. PubMed ID: 31727344
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin.
Algaze SD; Park W; Harrington TJ; Mudad R
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29523604
[TBL] [Abstract][Full Text] [Related]
10. Management of immune related adverse events induced by immune checkpoint inhibition.
Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N
Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
12. Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors.
Hamamoto Y; Shin N; Hoshino T; Kanai T
Future Oncol; 2018 Dec; 14(30):3187-3198. PubMed ID: 30188189
[TBL] [Abstract][Full Text] [Related]
13. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
14. [Management of Toxicities of Immune Checkpoint Inhibitors].
Horio Y
Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987
[TBL] [Abstract][Full Text] [Related]
15. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
Brahmer JR; Lacchetti C; Thompson JA
J Oncol Pract; 2018 Apr; 14(4):247-249. PubMed ID: 29517954
[No Abstract] [Full Text] [Related]
16. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
Safa H; Johnson DH; Trinh VA; Rodgers TE; Lin H; Suarez-Almazor ME; Fa'ak F; Saberian C; Yee C; Davies MA; Tummala S; Woodman K; Abdel-Wahab N; Diab A
J Immunother Cancer; 2019 Nov; 7(1):319. PubMed ID: 31753014
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy.
Palla AR; Kennedy D; Mosharraf H; Doll D
Case Rep Oncol; 2016; 9(3):691-697. PubMed ID: 27920704
[TBL] [Abstract][Full Text] [Related]
18. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
Moreira A; Loquai C; Pföhler C; Kähler KC; Knauss S; Heppt MV; Gutzmer R; Dimitriou F; Meier F; Mitzel-Rink H; Schuler G; Terheyden P; Thoms KM; Türk M; Dummer R; Zimmer L; Schröder R; Heinzerling L
Eur J Cancer; 2019 Jan; 106():12-23. PubMed ID: 30453170
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous adverse effects of the immune checkpoint inhibitors.
Collins LK; Chapman MS; Carter JB; Samie FH
Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]